Loading…
AVXL
Anavex Life Sciences Corp
NASDAQ· Healthcare· Biotechnology· CUSIP 032797300
$2.47+2.92%Price as of Sep 22, 22:38 UTC · updated once a day, after the close
Key metrics
- Market cap
- $228.96M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.0x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.14
- ROE
- -12.80%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.14
- 52-week high
- $10.38
- 52-week low
- $2.26
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -87.3% over 5Y.
today you would have $132.59▼ -86.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 20 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $3.56 | $10.74 | $9.31 | $9.26 | $17.34 | $5.40 | $2.59 | $1.56 | $3.22 | $3.96 | $5.57 | $0.74 | $1.00 | $3.16 | $4.88 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GLSIGreenwich LifeSciences, Inc. | $15.67 | — | 43.6x | — | -986.32% | $230.01M |
| KROSKeros Therapeutics, Inc. | $11.63 | — | 0.9x | — | -17.16% | $230.59M |
| ELMDElectromed, Inc. | $27.57 | 21.2x | 4.3x | — | 23.26% | $230.66M |
| CRDLCardiol Therapeutics Inc. | $1.94 |
About the company
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
- 34
- New York, United States
Company description provided by Yahoo Finance.